Vavricka John 4

What Happened

• John Vavricka, Chief Commercial Officer of Atea Pharmaceuticals (AVIR), received a grant of 119,520 restricted stock units (RSUs) and had derivative instruments converted/exercised on January 31, 2026. The filing shows 42,083 shares acquired via exercise/conversion and 53,653 shares disposed (11,570 withheld to cover taxes valued at $49,057; plus 33,333 and 8,750 shares reported as derivative dispositions at $0). Net effect in this report: an increase of 107,950 shares (161,603 acquired less 53,653 surrendered/withheld).

Key Details

• Transaction date: January 31, 2026; Form 4 filed February 3, 2026 (file appears timely).
• Tax withholding: 11,570 shares withheld at $4.24/share for $49,057 (code F).
• Acquisitions: 119,520 RSUs (code A) and 42,083 shares from exercise/conversion of derivatives (code M). Several derivative conversions/dispositions are shown at $0 (codes M).
• Net share change reported here: +107,950 shares (161,603 acquired – 53,653 disposed/withheld).
• Shares owned after transaction: not provided in the excerpt supplied.
• Footnotes: RSUs convert to one share each (F1). A prior 100,000 RSU grant fully vested as of 1/31/2026 (F2). Performance RSUs vested on 1/31/2026 (F3). A separate option grant vests monthly beginning after 1/31/2026 and fully vests 1/31/2030 (F4).

Context

• The report combines awards/vestings (RSUs) and derivative conversions/exercises—common for executives upon vesting. The tax withholding (F) shows shares surrendered to cover tax obligations; derivative dispositions at $0 often reflect net settlement mechanics rather than market sales. These filings are factual disclosures of compensation-related stock events and do not by themselves indicate insider market sentiment.